Catriona Yale - 09 Dec 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role: Chief Development Officer
Signature: /s/ Jonathan Young, Attorney-in-Fact
Issuer symbol: AKRO
Transactions as of: 09 Dec 2022
Net transactions value: -$216,137
Form type: 4
Filing time: 13 Dec 2022, 19:24:50 UTC
Previous filing: 14 Nov 2022
Next filing: 20 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AKRO	Common Stock	Award	$0	+19,195	+27%	$0.000000	91,268	09 Dec 2022	Direct	F1
transaction	AKRO	Common Stock	Sale	$198,542	-4,598	-5%	$43.18	86,670	12 Dec 2022	Direct	F2, F3
transaction	AKRO	Common Stock	Sale	$17,596	-402	-0.46%	$43.77	86,268	12 Dec 2022	Direct	F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AKRO	Stock Option (Right to Buy)	Award	$0	+86,379		$0.000000	86,379	09 Dec 2022	Common Stock	86,379	$42.95	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
F2	The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated December 30, 2021, previously adopted by the Reporting Person.
F3	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.68 to $43.67, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (3) and (4) to this Form 4.
F4	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.69 to $43.91, inclusive.
F5	This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing on December 9, 2022, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.